Professor T. Hugh Jones

BSc(Hons), MBChB, MD, FRCP(London), FRCP(Edinburgh)

School of Medicine and Population Health

Honorary Professor of Andrology

Consultant Physician in Diabetes and Endocrinology, Barnsley Hospital NHS Trust, Barnsley.

Hon. Consultant Endocrinologist, Endocrinology, Royal Hallamshire Hospital, Sheffield

t.h.jones@sheffield.ac.uk

+44 1226 431 684 (NHS Secretary)

The Medical School

Full contact details

Professor T. Hugh Jones
School of Medicine and Population Health
The Medical School
Beech Hill Road
Sheffield
S10 2RX

Profile

Hugh Jones is a world-leader researching the role of testosterone deficiency in the pathogenesis of Heart disease and Diabetes and the therapeutic benefits of testosterone replacement therapy in these conditions. He is a member of national and international guideline committees for the diagnosis and treatment of Male Testosterone Deficiency.

He studied Biochemistry BSc(Hons) (1972-1975) and then Medicine (1975-1980) at Sheffield University. I then trained as a junior doctor in Sheffield and Barnsley attaining MRCP(UK) 1984. This was followed by Clinical Research Fellow in the Department of Human Metabolism and Biochemistry (1985-1988) and then was appointing as Lecturer in Medicine both at University of Sheffield (1988-1993).As Consultant Physician with special interest in Diabetes and Endocrinology firstly in the Royal Hallamshire Hospital 1984-1998 and then Barnsley Hospital (1998 to present).

He has led clinical and laboratory teams which have made important contributions which include being first to demonstrate that testosterone reduces Insulin Resistance, improves glycaemic control (HbA1c) and quality of life in men with type 2 diabetes with hypogonadism. He identified that 40% of men with Type 2 Diabetes have symptomatic testosterone deficiency (male hypogonadism).

Professor Jones is one of the founder members of the international Androgen Society formed in 2017. He has been on the Guideline committees for Testosterone Deficiency and it s management for the European Association of Urology, British Society for Sexual Medicine and the International Consensus of Sexual Medicine. He has also been Chair of the Academic sub-committee for the Association of British Clinical Diabetologists, Chair Of Specialist Education Committee for spR training in Diabetes and Endocrinology for the Three Deaneries-Leicester, Nottingham and South Yorkshire, Training Programme Director for spR’s in Diabetes and Endocrinology in South Yorkshire.

Publications

Books

Jones T (2013) Testosterone Deficiency in Men.
Nieschlag E, Behre HM & Nieschlag S (2012) Testosterone Action, Deficiency, Substitution. Cambridge University Press.
Jones TH & Guaraldi F (2008) Advances in the Management of Testosterone Deficiency. Karger Medical and Scientific Publishers.
Jones H (2008) Testosterone Deficiency in Men. Oxford University Press, USA.

Journal articles

Morgentaler A, Dhindsa S, Dobs AS, Hackett G, Jones TH, Kloner RA, Miner M, Zitzmann M & Traish AM (2024) Androgen Society Position Paper on Cardiovascular Risk With Testosterone Therapy. Mayo Clinic Proceedings, 99(11), 1785-1801.
Mumdzic E, Rao P & Jones TH (2024) 8567 Clinical use of the androgen receptor sensitivity CAG repeat polymorphism to refine and improve the diagnosis of male hypogonadism. Journal of the Endocrine Society, 8(Supplement_1). View this article in WRRO
Williamson A, Bateman L, LeMaitre C, Jones TH, Aberdein N & Kelly DM (2024) 8711 The effect of testosterone therapy upon bone remodelling in testosterone deficient APOE-/- mice fed a high fat diet. Journal of the Endocrine Society, 8(Supplement_1). View this article in WRRO
JONES TH, HAIDER A, SULTAN HAIDER K, CULL ML & RYDER RE (2024) 895-P: Testosterone Replacement Therapy in Men with Hypogonadism and Type 2 Diabetes—ABCD Worldwide Audit. Diabetes, 73(Supplement_1).
Gül M, Luca B, Dimitropoulos K, Capogrosso P, Milenkovic U, Cocci A, Veeratterapillay R, Hatzichristodoulou G, Modgil V, Russo GI , Tharakan T et al (2024) What is the effectiveness of surgical and non-surgical therapies in the treatment of ischemic priapism in patients with sickle cell disease? A systematic review by the EAU Sexual and Reproductive Health Guidelines Panel. International Journal of Impotence Research, 36(1), 20-35.
Jones TH, Dobs AS, Randeva H, Moore W & Parkin JM (2023) Leflutrozole in male obesity-associated hypogonadotropic hypogonadism: Ph 2b double-blind randomised controlled trial. European Journal of Endocrinology, 189(3), 297-308.
Hackett G, Kirby M, Rees RW, Jones TH, Muneer A, Livingston M, Ossei-Gerning N, David J, Foster J, Kalra PA & Ramachandran S (2023) The British Society for Sexual Medicine Guidelines on Male Adult Testosterone Deficiency, with Statements for Practice. The World Journal of Men's Health, 41(3), 508-508.
Mohan Rao P, Mumdzic E, Kelly DM & Hugh Jones T (2022) RF34 | PMON263 Study of Testosterone Replacement in Hypogonadal Men With Uncontrolled Type 2 Diabetes – a Randomised Double Blinded Placebo Controlled Trial (STRIDE Study). Journal of the Endocrine Society, 6(Supplement_1), A717-A717.
Perros P, Basu A, Boelaert K, Dayan C, Vaidya B, Williams GR, Lazarus JH, Hickey J, Drake WM, Crown A , Orme SM et al (2022) Postradioiodine Graves' management: The PRAGMA study. Clinical Endocrinology, 97(5), 664-675.
Grossmann M & Jones TH (2021) Functional hypogonadism in middle-aged and older men: testosterone treatment or not?. European Journal of Endocrinology, 185(3), D1-D9.
Salonia A, Bettocchi C, Boeri L, Capogrosso P, Carvalho J, Cilesiz NC, Cocci A, Corona G, Dimitropoulos K, Gül M , Hatzichristodoulou G et al (2021) European Association of Urology Guidelines on Sexual and Reproductive Health—2021 Update: Male Sexual Dysfunction. European Urology, 80(3), 333-357.
Kilby EL, Kelly DM & Jones TH (2021) Testosterone stimulates cholesterol clearance from human macrophages by activating LXRα. Life Sciences, 269, 119040-119040.
Bateman L, Rao P, Jones TH & Kelly DM (2020) SAT-049 Testosterone Therapy Reduces Inflammatory Activation of Human Monocytes in Hypogonadal Type-2 Diabetic Men as a Potential Mechanism to Improve Atherosclerosis. Journal of the Endocrine Society, 4(Supplement_1).
Mumdzic E, Rao PM & Jones TH (2020) SAT-030 The Barnsley Diabetes Hypogonadal Questionnaire (BDHQ) - Validation for the Clinical Use to Support the Diagnosis of Testosterone Deficiency in Men with Type 2 Diabetes (T2D). Journal of the Endocrine Society, 4(Supplement_1).
Rao PM, Mumdzic E, Kelly DM & Jones TH (2020) SAT-051 Effects of Testosterone Replacement on Glycemic Control and Other Cardiovascular Risk Factors in Hypogonadal Men with Uncontrolled Type 2 Diabetes (Stride Study): Design, Implementation and Baseline Data. Journal of the Endocrine Society, 4(Supplement_1).
Bateman L, Dalton C, Maitre CL, Jones TH & Kelly DM (2020) SAT-041 Testosterone Reduces Atherosclerosis and Plaque Specific Inflammatory Markers in the ApoE-/- Mouse Model. Journal of the Endocrine Society, 4(Supplement_1).
Morgentaler A, Traish A, Hackett G, Jones TH & Ramasamy R (2019) Diagnosis and Treatment of Testosterone Deficiency: Updated Recommendations From the Lisbon 2018 International Consultation for Sexual Medicine. Sexual Medicine Reviews, 7(4), 636-649.
Mumdzic E, Morganti E, Gowda S, Rao P & Jones T (2019) SUN-237 Higher Doses of Testosterone Gel Required in Hypogonadal Men with Obesity to Achieve Therapeutic Replacement - Advice on Dose Titration. Journal of the Endocrine Society, 3(Supplement_1).
Bateman L, Jones T & Kelly D (2019) SUN-224 Testosterone Reduces Expression of Inflammatory Targets in Human Macrophages as a Potential Mechanism to Improve Atherosclerosis. Journal of the Endocrine Society, 3(Supplement_1).
Kelly D, Nettleship J & Jones T (2019) SAT-001 Supra-Physiological Testosterone Treatment Reduces Aortic Atheroma but Increases Markers of Cardiac Hypertrophy. Journal of the Endocrine Society, 3(Supplement_1).
Church D, Cardoso L, Kay RG, Williams CL, Freudenthal B, Clarke C, Harris J, Moorthy M, Karra E, Gribble FM , Reimann F et al (2018) Assessment and Management of Anti-Insulin Autoantibodies in Varying Presentations of Insulin Autoimmune Syndrome. The Journal of Clinical Endocrinology & Metabolism, 103(10), 3845-3855.
Arver S, Stief C, de la Rosette J, Jones TH, Neijber A & Carrara D (2018) A new 2% testosterone gel formulation: a comparison with currently available topical preparations. Andrology, 6(3), 396-407.
Jones TH & Kelly DM (2018) Randomized controlled trials-mechanistic studies of testosterone and the cardiovascular system. Asian Journal of Andrology, 20(2), 120-130.
Jones T & Kelly D (2018) Randomized controlled trials – mechanistic studies of testosterone and the cardiovascular system. Asian Journal of Andrology, 20(2), 120-120.
Dimitriadis GK, Randeva HS, Aftab S, Ali A, Hattersley JG, Pandey S, Grammatopoulos DK, Valsamakis G, Mastorakos G, Jones TH & Barber TM (2018) Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy. Endocrine, 60(1), 175-184.
Hackett G, Kirby M, Edwards D, Jones TH, Wylie K, Ossei-Gerning N, David J & Muneer A (2017) British Society for Sexual Medicine Guidelines on Adult Testosterone Deficiency, With Statements for UK Practice. Journal of Sexual Medicine, 14(12), 1504-1523. View this article in WRRO
Hackett G, Kirby M, Edwards D, Jones TH, Rees J & Muneer A (2017) UK policy statements on testosterone deficiency. International Journal of Clinical Practice, 71(3-4). View this article in WRRO
Kelly DM, Akhtar S, Sellers DJ, Muraleedharan V, Channer KS & Jones TH (2016) Testosterone differentially regulates targets of lipid and glucose metabolism in liver, muscle and adipose tissues of the testicular feminised mouse.. Endocrine. View this article in WRRO
Gosai JN, Charalampidis P, Nikolaidou T, Parviz Y, Morris PD, Channer KS, Jones TH & Grech ED (2016) Revascularization with percutaneous coronary intervention does not affect androgen status in males with chronic stable angina pectoris. Andrology, 4(3), 486-491.
Kelly DM & Jones TH (2015) Testosterone and obesity. Obesity Reviews, 16(7), 581-606.
Jones TH (2015) Testosterone and cardiovascular disease. Heart and Metabolism(66), 7-12.
Jones TH (2014) Comment on Gianatti et al. Effect of Testosterone Treatment on Glucose Metabolism in Men With Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care 2014;37:2098–2107. Diabetes Care, 37(12), e267-e268.
Zarotsky V, Huang M, Carman W, Morgentaler A, Singhal PK, Coffin D & Jones TH (2014) Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. Andrology, 2(6), 819-834.
Zarotsky V, Huang M-Y, Carman W, Morgentaler A, Singhal PK, Coffin D & Jones TH (2014) Systematic Literature Review of the Epidemiology of Nongenetic Forms of Hypogonadism in Adult Males. Journal of Hormones, 2014, 1-17.
Muraleedharan V & Hugh Jones T (2014) Testosterone and mortality. Clinical Endocrinology, 81(4), 477-487.
Kelly DM, Nettleship JE, Akhtar S, Muraleedharan V, Sellers DJ, Brooke JC, McLaren DS, Channer KS & Jones TH (2014) Testosterone suppresses the expression of regulatory enzymes of fatty acid synthesis and protects against hepatic steatosis in cholesterol-fed androgen deficient mice. Life Sciences, 109(2), 95-103.
Kelly DM & Jones TH (2014) Testosterone and Cardiovascular Risk in Men, 1-20.
Jones TH & Channer KS (2014) Deaths and Cardiovascular Events in Men Receiving Testosterone. JAMA, 311(9), 962-962.
Brooke JC, Walter DJ, Kapoor D, Marsh H, Muraleedharan V & Jones TH (2014) Testosterone deficiency and severity of erectile dysfunction are independently associated with reduced quality of life in men with type 2 diabetes. Andrology, 2(2), 205-211.
Jones TH (2014) Testosterone and cardiovascular disease. The Lancet Diabetes & Endocrinology, 2(8), 612-613.
Stanworth RD, Akhtar S, Channer KS & Jones TH (2014) The role of androgen receptor CAG repeat polymorphism and other factors which affect the clinical response to testosterone replacement in metabolic syndrome and type 2 diabetes: TIMES2 sub-study. European Journal of Endocrinology, 170(2), 193-200.
Muraleedharan V, Marsh H, Kapoor D, Channer KS & Jones TH (2013) Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. European Journal of Endocrinology, 169(6), 725-733.
Rao PM, Kelly DM & Jones TH (2013) Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. Nature Reviews Endocrinology, 9(8), 479-493.
Kelly DM & Jones TH (2013) Testosterone: a vascular hormone in health and disease. Journal of Endocrinology, 217(3), R47-R71.
Kelly DM & Jones TH (2013) Testosterone: a metabolic hormone in health and disease. Journal of Endocrinology, 217(3), R25-R45.
Jones TH, Howell JD & Channer KS (2011) Response to Comment on: Jones et al. Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study). Diabetes Care 2011;34:828–837. Diabetes Care, 34(11), e173-e173.
Wang C, Jackson G, Jones TH, Matsumoto AM, Nehra A, Perelman MA, Swerdloff RS, Traish A, Zitzmann M & Cunningham G (2011) Low Testosterone Associated With Obesity and the Metabolic Syndrome Contributes to Sexual Dysfunction and Cardiovascular Disease Risk in Men With Type 2 Diabetes. Diabetes Care, 34(7), 1669-1675.
Stanworth RD, Kapoor D, Channer KS & Jones TH (2011) Dyslipidaemia is associated with testosterone, oestradiol and androgen receptor CAG repeat polymorphism in men with type 2 diabetes. Clinical Endocrinology, 74(5), 624-630.
Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, Morales AM, Volterrani M, Yellowlees A, Howell JD & Channer KS (2011) Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study). Diabetes Care, 34(4), 828-837.
Jones TH, Quinton R & Ullah A (2011) ‘Every obese male with type 2 diabetes should be screened for hypogonadism’. Practical Diabetes International, 28(1), 14-14.
Debono M, Chan S, Rolfe C & Jones TH (2011) Tramadol-induced adrenal insufficiency. European Journal of Clinical Pharmacology, 67(8), 865-867.
Muraleedharan V & Jones TH (2010) Review: Testosterone and the metabolic syndrome. Therapeutic Advances in Endocrinology and Metabolism, 1(5), 207-223.
Dhatariya K, Nagi D & Jones TH (2010) ABCD position statement on the management of hypogonadal males with type 2 diabetes. Practical Diabetes International, 27(9), 408-412.
Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH & Channer KS (2010) Low serum testosterone and increased mortality in men with coronary heart disease. Heart, 96(22), 1821-1825.
Muraleedharan V, Marsh H & Jones TH (2010) Testosterone Deficiency is Associated with Increased Mortality in Men with Type 2 Diabetes – A Six Year follow up Study. Journal of Men's Health, 7(3), 319-319.
JONES TH (2010) Effects of testosterone on Type 2 diabetes and components of the metabolic syndrome. Journal of Diabetes, 2(3), 146-156.
Malkin CJ, Channer KS & Jones TH (2010) Testosterone and heart failure. Current Opinion in Endocrinology, Diabetes & Obesity, 17(3), 262-268.
Jones TH (2010) Testosterone deficiency: a risk factor for cardiovascular disease?. Trends in Endocrinology & Metabolism, 21(8), 496-503.
Hugh Jones T (2010) ‘What should I do with a 60‐year old man with a slightly low serum total testosterone concentration and normal levels of serum gonadotrophins’?. Clinical Endocrinology, 72(5), 584-588.
Jones TH (2009) 202More than 8 years of experience in treating men with Type 2 Diabetes with Testosterone. Journal of Men's Health, 6(4), 398-398.
Mathur A, Malkin C, Saeed B, Muthusamy R, Jones TH & Channer K (2009) Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. European Journal of Endocrinology, 161(4), 653-653.
Mathur A, Malkin C, Saeed B, Muthusamy R, Jones TH & Channer K (2009) Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. European Journal of Endocrinology, 161(3), 443-449.
Rowell KO, Hall J, Pugh PJ, Jones TH, Channer KS & Jones RD (2009) Testosterone acts as an efficacious vasodilator in isolated human pulmonary arteries and veins: Evidence for a biphasic effect at physiological and supra-physiological concentrations. Journal of Endocrinological Investigation, 32(9), 718-723.
Jones TH & Saad F (2009) The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis, 207(2), 318-327.
Hall J, Jones TH, Channer KS & Jones RD (2009) Mechanisms of agonist-induced constriction in isolated human pulmonary arteries. Vascular Pharmacology, 51(1), 8-12.
Stanworth RD, Kapoor D, Channer KS & Jones TH (2009) Statin Therapy Is Associated With Lower Total but Not Bioavailable or Free Testosterone in Men With Type 2 Diabetes. Diabetes Care, 32(4), 541-546.
Kapoor D & Jones TH (2008) Androgen Deficiency as a Predictor of Metabolic Syndrome in Aging Men. Drugs & Aging, 25(5), 357-369.
Smith AM, Bennett RT, Jones TH, Cowen ME, Channer KS & Jones RD (2008) Characterization of the vasodilatory action of testosterone in the human pulmonary circulation. Vascular Health and Risk Management, 4(6), 1459-1466.
Jones TH (2008) Introduction, 1-4.
Stanworth RD & Jones TH (2008) Testosterone in Obesity, Metabolic Syndrome and Type 2 Diabetes, 74-90.
Malkin CJ, Jones TH & Channer KS (2008) Testosterone in Chronic Heart Failure, 183-196.
Nettleship JE, Jones RD, Channer KS & Jones TH (2008) Testosterone and Coronary Artery Disease, 91-107.
Stanworth RD, Kapoor D, Channer KS & Jones TH (2008) Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes. European Journal of Endocrinology, 159(6), 739-746.
Jones TH (2008) Clinical awareness and diagnosis of male hypogonadism. Journal of Men's Health, 5(S), S26-S34.
Kapoor D, Channer KS & Jones TH (2008) Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes. Diabetes and Vascular Disease Research, 5(2), 135-137.
Nettleship JE, Jones TH, Channer KS & Jones RD (2007) Physiological Testosterone Replacement Therapy Attenuates Fatty Streak Formation and Improves High-Density Lipoprotein Cholesterol in the Tfm Mouse. Circulation, 116(21), 2427-2434.
Jones TH (2007) Testosterone Associations with Erectile Dysfunction, Diabetes, and the Metabolic Syndrome. European Urology Supplements, 6(16), 847-857.
Kapoor D, Clarke S, Channer KS & Jones TH (2007) Erectile dysfunction is associated with low bioactive testosterone levels and visceral adiposity in men with type 2 diabetes. International Journal of Andrology, 30(6), 500-507.
Jones TH (2007) Hypogonadism in men with type 2 diabetes. Practical Diabetes International, 24(5), 269-277.
Kapoor D, Clarke S, Stanworth R, Channer KS & Jones TH (2007) The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. European Journal of Endocrinology, 156(5), 595-602.
Nettleship J, Pugh P, Channer K, Jones T & Jones R (2007) Inverse Relationship between Serum Levels of Interleukin-1β and Testosterone in Men with Stable Coronary Artery Disease. Hormone and Metabolic Research, 39(5), 366-371.
Kapoor D, Aldred H, Clark S, Channer KS & Jones TH (2007) Clinical and Biochemical Assessment of Hypogonadism in Men With Type 2 Diabetes. Diabetes Care, 30(4), 911-917.
Malkin CJ, Jones TH & Channer KS (2007) The effect of testosterone on insulin sensitivity in men with heart failure. European Journal of Heart Failure, 9(1), 44-50.
Jones TH (2007) Testosterone replacement therapy. British Journal of Hospital Medicine, 68(10), 547-553.
Malkin CJ, Jones RD, Jones TH & Channer KS (2006) Effect of testosterone on ex vivo vascular reactivity in man. Clinical Science, 111(4), 265-274.
Kapoor D, Goodwin E, Channer KS & Jones TH (2006) Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. European Journal of Endocrinology, 154(6), 899-906.
Hall J, Jones TH, Channer KS & Jones RD (2006) Mechanisms of agonist-induced constriction in isolated human mesenteric arteries. Vascular Pharmacology, 44(6), 427-433.
Hall J, Jones RD, Jones TH, Channer KS & Peers C (2006) Selective Inhibition of L-Type Ca2+ Channels in A7r5 Cells by Physiological Levels of Testosterone. Endocrinology, 147(6), 2675-2680.
Smith AM, Morris P, Rowell KO, Clarke S, Jones TH & Channer KS (2006) Junior doctors and the full shift rota – psychological and hormonal changes: a comparative cross-sectional study. Clinical Medicine, 6(2), 174-177.
Malkin CJ, Pugh PJ, West JN, van Beek EJR, Jones TH & Channer KS (2006) Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. European Heart Journal, 27(1), 57-64.
Pugh PJ, Jones RD, Malkin CJ, Hall J, Nettleship JE, Kerry KE, Hugh Jones T & Channer KS (2005) Physiologic Testosterone Therapy has no Effect on Serum Levels of Tumour Necrosis Factor-α in Men with Chronic Heart Failure. Endocrine Research, 31(4), 271-283.
Kapoor D, Malkin CJ, Channer KS & Jones TH (2005) Androgens, insulin resistance and vascular disease in men. Clinical Endocrinology, 63(3), 239-250.
Kapoor D & Jones TH (2005) Smoking and hormones in health and endocrine disorders. European Journal of Endocrinology, 152(4), 491-499.
Borg SA, Kerry KE, Royds JA, Battersby RD & Jones TH (2005) Correlation of VEGF production with IL1α and IL6 secretion by human pituitary adenoma cells. European Journal of Endocrinology, 152(2), 293-300.
Smith AM, English KM, Malkin CJ, Jones RD, Jones TH & Channer KS (2005) Testosterone does not adversely affect fibrinogen or tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) levels in 46 men with chronic stable angina. European Journal of Endocrinology, 152(2), 285-291.
Jones RD, Jones TH & Channer KS (2004) Replacement therapy, not recreational tonic. Nature, 432(7016), 439-439.
Morris PD, Malkin CJ, Channer KS & Jones TH (2004) A mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men. European Journal of Endocrinology, 241-249.
JONES RD, ENGLISH KM, JONES TH & CHANNER KS (2004) Testosterone-induced coronary vasodilatation occurs via a non-genomic mechanism: evidence of a direct calcium antagonism action. Clinical Science, 107(2), 149-158.
Malkin CJ (2004) Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart, 90(8), 871-876.
Jones RD, Hugh Jones T & Channer KS (2004) The influence of testosterone upon vascular reactivity. European Journal of Endocrinology, 29-37.
Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS & Jones TH (2004) The Effect of Testosterone Replacement on Endogenous Inflammatory Cytokines and Lipid Profiles in Hypogonadal Men. The Journal of Clinical Endocrinology & Metabolism, 89(7), 3313-3318.
Scragg JL, Jones RD, Channer KS, Jones TH & Peers C (2004) Testosterone is a potent inhibitor of L-type Ca2+ channels. Biochemical and Biophysical Research Communications, 318(2), 503-506.
Pugh PJ (2004) Testosterone treatment for men with chronic heart failure. Heart, 90(4), 446-447.
Ross RJ, Jabbar A, Jones TH, Roberts B, Dunkley K, Hall J, Long A, Levine H & Cullen DR (2004) Pharmacokinetics and tolerability of a bioadhesive buccal testosterone tablet in hypogonadal men. European Journal of Endocrinology, 57-63.
Jones RD, Pugh PJ, Jones TH & Channer KS (2003) The vasodilatory action of testosterone: a potassium‐channel opening or a calcium antagonistic action?. British Journal of Pharmacology, 138(5), 733-744.
Morris DG, Kola B, Borboli N, Kaltsas GA, Gueorguiev M, McNicol AM, Ferrier R, Jones TH, Baldeweg S, Powell M , Czirják S et al (2003) Identification of Adrenocorticotropin Receptor Messenger Ribonucleic Acid in the Human Pituitary and Its Loss of Expression in Pituitary Adenomas. The Journal of Clinical Endocrinology & Metabolism, 88(12), 6080-6087.
Borg SA, Kerry KE, Baxter L, Royds JA & Jones TH (2003) Expression of Interleukin-6 and Its Effects on Growth of HP75 Human Pituitary Tumor Cells. The Journal of Clinical Endocrinology & Metabolism, 88(10), 4938-4944.
Jones RD, Ruban LN, Morton IE, Roberts SA, English KM, Channer KS & Jones TH (2003) Testosterone inhibits the prostaglandin F2alpha-mediated increase in intracellular calcium in A7r5 aortic smooth muscle cells: evidence of an antagonistic action upon store-operated calcium channels. Journal of Endocrinology, 178(3), 381-393.
Malkin CJ, Pugh PJ, Jones RD, Jones TH & Channer KS (2003) Testosterone as a protective factor against atherosclerosis--immunomodulation and influence upon plaque development and stability. Journal of Endocrinology, 178(3), 373-380.
Malkin CJ, Pugh PJ, Jones TH & Channer KS (2003) Testosterone for secondary prevention in men with ischaemic heart disease?. QJM, 96(7), 521-529.
Pugh P (2003) Acute haemodynamic effects of testosterone in men with chronic heart failure. European Heart Journal, 24(10), 909-915.
Jones RD, Malkin CJ, Channer KS & Jones TH (2003) Low Levels of Endogenous Androgens Increase the Risk of Atherosclerosis in Elderly Men: Further Supportive Data. The Journal of Clinical Endocrinology & Metabolism, 88(3), 1403-1404.
Channer KS (2003) Cardiovascular effects of testosterone: implications of the "male menopause"?. Heart, 89(2), 121-122.
Jones RD, Pugh PJ, Hall J, Channer KS & Jones TH (2003) Altered circulating hormone levels, endothelial function and vascular reactivity in the testicular feminised mouse. European Journal of Endocrinology, 111-120.
English KM, Jones RD, Jones TH, Morice AH & Channer KS (2002) Testosterone acts as a coronary vasodilator by a calcium antagonistic action. Journal of Endocrinological Investigation, 25(5), 455-458.
Pugh PJ, Channer KS, Parry H, Downes T & Hugh Jones T (2002) BIO-AVAILABLE TESTOSTERONE LEVELS FALL ACUTELY FOLLOWING MYOCARDIAL INFARCTION IN MEN: ASSOCIATION WITH FIBRINOLYTIC FACTORS. Endocrine Research, 28(3), 161-173.
Pugh PJ, Jones RD, Jones TH & Channer KS (2002) Heart failure as an inflammatory condition: potential role for androgens as immune modulators. European Journal of Heart Failure, 4(6), 673-680.
Pugh PJ, Jones RD, Jones TH & Channer KS (2002) Plasma Androgens and Heart Rate Variability in Men with Heart Failure. Clinical Science, 103(s47), 6P-6P.
Jones RD, English KM, Pugh PJ, Morice AH, Jones TH & Channer KS (2002) Pulmonary Vasodilatory Action of Testosterone: Evidence of a Calcium Antagonistic Action. Journal of Cardiovascular Pharmacology, 39(6), 814-823.
Pugh PJ, Jones RD, Jones TH & Channer KS (2002) Shuttle Walk Test in Patients with Heart Failure: Relationship with Haemodynamic Parameters and Symptoms. Clinical Science, 102(s46), 5P-6P.
Morris PD, Pugh PJ, Jones TH & Channer KS (2002) Diabetes and Low Testosterone in Men with Coronary Artery Disease. Clinical Science, 102(s46), 5P-5P.
Korbonits M, Chitnis MM, Gueorguiev M, Norman D, Rosenfelder N, Suliman M, Jones TH, Fabbri KNA, Besser GM, Burrin JM & Grossman AB (2001) The release of leptin and its effect on hormone release from human pituitary adenomas. Clinical Endocrinology, 54(6), 781-789.
English KM, Jones RD, Jones TH, Morice AH & Channer KS (2001) Gender Differences in the Vasomotor Effects of Different Steroid Hormones in Rat Pulmonary and Coronary Arteries. Hormone and Metabolic Research, 33(11), 645-652.
Suliman M, Royds J, Cullen D, Timperley W, Powell T, Battersby R & Jones TH (2001) Mdm2 and the p53 pathway in human pituitary adenomas. Clinical Endocrinology, 54(3), 317-325.
Pugh PJ, Jones RD, Jones TH & Channer KS (2001) Development of Intrinsic Tone in Rat Coronary Arteries IN-VITRO. Clinical Science, 101(s45), 4P-4P.
ENGLISH KM, PUGH PJ, PARRY H, SCUTT NE, CHANNER KS & JONES TH (2001) Effect of cigarette smoking on levels of bioavailable testosterone in healthy men. Clinical Science, 100(6), 661-661.
English K (2001) A reply. European Heart Journal, 22(7), 613-613.
English KM, Steeds RP, Jones TH, Diver MJ & Channer KS (2000) Low-Dose Transdermal Testosterone Therapy Improves Angina Threshold in Men With Chronic Stable Angina. Circulation, 102(16), 1906-1911.
Pugh PJ, English KM, Jones TH & Channer KS (2000) Testosterone: a natural tonic for the failing heart?. QJM: An International Journal of Medicine, 93(10), 689-694.
ENGLISH KM, JONES RD, JONES TH, MORICE AH & CHANNER KS (2000) Aging reduces the responsiveness of coronary arteries from male Wistar rats to the vasodilatory action of testosterone. Clinical Science, 99(1), 77-77.
English K (2000) Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. European Heart Journal, 21(11), 890-894.
Adeniji AA, Fairlie FM, Jones TH & Wilkinson P (1999) Pregnancy and blue rubber bleb naevus syndrome. BJOG: An International Journal of Obstetrics & Gynaecology, 106(12), 1316-1318.
Suliman ME, Royds JA, Baxter L, Timperley WR, Cullen DR & Jones TH (1999) IL-8 mRNA expression by in situ hybridisation in human pituitary adenomas. European Journal of Endocrinology, 155-158.
Jones TH, Wadler S & Hupart KH (1998) Endocrine-mediated mechanisms of fatigue during treatment with interferon-alpha.. Semin Oncol, 25(1 Suppl 1), 54-63.
Jones TH, Wadler S & Hupart KH (1998) Endocrine-mediated mechanisms of fatigue during treatment with interferon-α. SEMINARS IN ONCOLOGY, 25(1), 54-63.
Jones TH, Justice SK, Timperley WR & Royds JA (1997) Effects of interleukin-1 and dexamethasone on interleukin-6 production and growth in human meningiomas. The Journal of Pathology, 183(4), 460-468.
English KM, Steeds R, Jones TH & Channer KS (1997) Testosterone and coronary heart disease: is there a link?. QJM, 90(12), 787-791.
Jones TH, Kennedy RL, Justice SK & Davies R (1997) Effect of glucocorticoids and oestrogen on interleukin-6 production by human thyrocytes from patients with Graves' disease and toxic multinodular goitre and from HTori3 cells. European Journal of Endocrinology, 429-432.
Jones TH, Justice SK & Price A (1997) Suppression of tyrosine kinase activity inhibits [3H]thymidine uptake in cultured human pituitary tumor cells.. J Clin Endocrinol Metab, 82(7), 2143-2147.
Guo C-Y (1997) Treatment of Isolated Hypogonadotropic Hypogonadism Effect on Bone Mineral Density and Bone Turnover. Journal of Clinical Endocrinology & Metabolism, 82(2), 658-665.
Jones TH (1995) The management of hyperprolactinaemia.. British Journal of Hospital Medicine, 53(8), 374-378.
Jones TH, Hunter SM, Price A & Angelini GD (1995) Reply. The Annals of Thoracic Surgery, 59(5), 1274-1275.
Jones TH (1994) Interleukin‐6 an endocrine cytokine. Clinical Endocrinology, 40(6), 703-713.
Jones TH & Fraser RB (1994) Cabergoline treated hyperprolactinaemia results in pregnancy in a bromocriptine intolerant patient after seventeen years of infertility. BJOG: An International Journal of Obstetrics & Gynaecology, 101(4), 349-350.
Jones TH, Darne JF & McGarrigle HHG (1994) Diurnal rhythm of testosterone induced by human chorionic gonadotrophin (hCG) therapy in isolated hypogonadotrophic hypogonadism: a comparison between subcutaneous and intramuscular hCG administration. European Journal of Endocrinology, 131(2), 173-178.
Jones TH, Hunter SM, Price A & Angelini GD (1994) Should thyroid function be assessed before cardiopulmonary bypass operations?. The Annals of Thoracic Surgery, 58(2), 434-436.
Jones TH, Daniels M, James RA, Justice SK, McCorkle R, Price A, Kendall-Taylor P & Weetman AP (1994) Production of bioactive and immunoreactive interleukin-6 (IL-6) and expression of IL-6 messenger ribonucleic acid by human pituitary adenomas.. The Journal of Clinical Endocrinology & Metabolism, 78(1), 180-187.
Jones TH, Kennedy RL, Justice SK & Price A (1993) Pituitary adenomas with high and low basal inositol phospholipid turnover; the stimulatory effect of kinins and an association with interleukin‐6 secretion. Clinical Endocrinology, 39(4), 433-439.
Jones TH & Darne JF (1993) Self‐administered subcutaneous human menopausal gonadotrophin for the stimulation of testicular growth and the initiation of spermatogenesis in hypogonadotrophic hypogonadism. Clinical Endocrinology, 38(2), 203-208.
Jones TH & Kennedy RL (1993) Cytokines and hypothalamic-pituitary function. Cytokine, 5(6), 531-538.
Jones TH, Kennedy RL, Justice SK & Price A (1993) Interleukin-1 stimulates the release of interleukin-6 from cultured human pituitary adenoma cells. Acta Endocrinologica, 128(5), 405-410.
Jones TH, Brown BL, Cullen DR & Dobson PRM (1992) Effect of the GABA<sub>A</sub> Agonist Muscimol on Prolactin Secretion from Human Prolactin-Secreting Adenomas and GH<sub>3</sub> Rat Pituitary Tumour Cells. Hormone Research, 37(3), 113-118.
Kennedy RL, Jones TH & Cuckle HS (1992) Down's syndrome and the thyroid. Clinical Endocrinology, 37(6), 471-476.
Jones TH, Figueroa CD & Bhoola KD (1992) Bioregulatory role of the kallikrein-kinin system in the normal pituitary gland and its tumours. Acta Endocrinologica, 127(6), 481-484.
Jones TH, Figueroa CD, Smith CM, Cullen DR & Bhoola KD (1992) Tissue kallikrein is associated with prolactin-secreting cells within human growth hormone-secreting adenomas. Journal of Endocrinology, 134(1), 149-NP.
Kennedy RL, Davies R, Macneil S, Jones TH & Lemoine NR (1992) Transformation of Thyrocytes with RAS Oncogene Alters Intracellular Free Calcium Concentration and the Response to Growth Factors. Clinical Science, 83(s27), 1P-2P.
Kennedy RL, Jones TH, Davies R, Justice SK & Lemoine NR (1992) Release of interleukin-6 by human thyroid epithelial cells immortalized by simian virus 40 DNA transfection. Journal of Endocrinology, 133(3), 477-482.
Rahman S, Bunning RAD, Dobson PRM, Evans DB, Chapman K, Jones TH, Brown BL & Russell RGG (1992) Bradykinin stimulates the production of prostaglandin E2 and interleukin-6 in human osteoblast-like cells. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1135(1), 97-102.
Jones TH, Figueroa CD, Smith CM & Bhoola KD (1992) Tissue kallikrein and the effect of bromocriptine in human prolactin and growth hormone-secreting pituitary adenomas.. Agents Actions Suppl, 38 ( Pt 2), 175-182.
Jones TH (1991) Sodium Valproate-Induced Menstrual Disturbance in Young Women. Hormone Research, 35(2), 82-85.
Jones TH, Kennedy RL, Cullen DR & Smith CML (1991) Identification of Clinically Important Novel types of Prolactin and Growth Hormone-Secreting Pituitary Macroadenomas. Clinical Science, 81(s25), 11P-12P.
Kennedy RL & Jones TH (1991) Cytokines in endocrinology: their roles in health and in disease. Journal of Endocrinology, 129(2), 167-178.
JONES TH, JUSTICE S, PRICE A & CHAPMAN K (1991) INTERLEUKIN-6 SECRETING HUMAN PITUITARY ADENOMASIN VITRO. The Journal of Clinical Endocrinology & Metabolism, 73(1), 207-209.
Jones TH, Bergvall V & Bradshaw JPP (1990) Carotid artery stenoses and thrombosis secondary to cavernous sinus thromboses in Fusobacterium necrophorum meningitis. Postgraduate Medical Journal, 66(779), 747-750.
Jones TH, Brown BL & Dobson PRM (1990) Kallidin-induced stimulation of inositol phosphate production and prolactin release in rat anterior pituitary cells. Acta Endocrinologica, 123(1), 37-42.
Jones TH, Figueroa CD, Smith C, Cullen DR & Bhoola KD (1990) Characterization of a tissue kallikrein in human prolactin-secreting adenomas. Journal of Endocrinology, 124(2), 327-NP.
Jones TH, Brown BL & Dobson PRM (1990) Paracrine control of anterior pituitary hormone secretion. Journal of Endocrinology, 127(1), 5-13.
(1989) Diagnosis of adrenal insufficiency.. BMJ, 298(6674), 668-670.
Jones TH, Brown BL & Dobson PRM (1989) Bradykinin stimulates phosphoinositide metabolism and prolactin secretion in rat anterior pituitary cells. Journal of Molecular Endocrinology, 2(1), 47-53.
Jones TH & Kennedy RL (1988) Hyperprolactinaemia.. BMJ, 297(6658), 1268-1268.
Kennedy RL, Jones TH & Shaukat HN (1988) Amiodarone and thyroid immunity.. BMJ, 297(6648), 621-622.
Kennedy RL & Jones TH (1988) Graves' disease. BMJ, 296(6637), 1670-1671.
Jones TH, Brown BL & Dobson PRM (1988) Evidence that angiotensin II is a paracrine agent mediating gonadotrophin-releasing hormone-stimulated inositol phosphate production and prolactin secretion in the rat. Journal of Endocrinology, 116(3), 367-371.
Jones TH, Kanis JA & Yates AJ (1985) Hypercalcaemia complicating polyneuropathy.. Journal of Neurology, Neurosurgery & Psychiatry, 48(4), 390-391.
Yates AJ, Jones TH, Mundy KI, Hague RV, Brown CB, Guilland-Cumming D & Kanis JA (1984) Immobilisation hypercalcaemia in adults and treatment with clodronate.. BMJ, 289(6452), 1111-1112.
Austin CA, Cann PA, Jones TH & Holdsworth CD (1984) EXACERBATION OF DIARRHOEA AND PAIN IN PATIENTS TREATED WITH 5-AMINOSALICYLIC ACID FOR ULCERATIVE COLITIS. The Lancet, 323(8382), 917-918.
Mumdzic E, Muraleedharan V, Kelly DM, Kapoor D & Jones TH () The impact of testosterone level on body composition in men with type 2 diabetes (T2D). Endocrine Abstracts.
Kelly D, Akhtar S, Muraleedharan V, Brooke J, McLaren D, Channer K & Jones TH () Testosterone differentially regulates liver X receptor expression and targets of lipid and glucose metabolism in liver, muscle and adipose tissue of the testicular feminised mouse. Endocrine Abstracts.
Kelly D, Muraleedharan V, Akhtar S, Channer K & Jones TH () Testosterone differentially regulates lipid and glucose metabolism in visceral and subcutaneous fat in the testicular feminised mouse. Endocrine Abstracts, 1-1.
Jones H () Testosterone for the aging male; current evidence and recommended practice. Clinical Interventions in Aging, Volume 3, 25-44.
Pugh PJ, Jones RD, Jones TH & Channer KS () Intrinsic Responses of Rat Coronary Arteries In Vitro : Influence of Testosterone, Calcium, and Effective Transmural Pressure. Endocrine, 19(2), 155-162.

Chapters

Jones TH & Channer KS (2012) Testosterone, obesity, diabetes and the metabolic syndrome, Testosterone (pp. 235-250). Cambridge University Press
Channer KS & Jones TH (2012) Testosterone and cardiovascular disease, Testosterone (pp. 207-234). Cambridge University Press

Conference proceedings papers

Rao PM, Jones TH & Kelly D (2023) Testosterone improves symptom severity, quality of life (QOL), triglycerides and strength: A randomised placebo-controlled study in men with uncontrolled type-2 diabetes and hypogonadism: Stride study. DIABETIC MEDICINE, Vol. 40
Gul M, Luca B, Dimitropoulos K, Capogrosso P, Milenkovic U, Cocci A, Veeratterapillay R, Hatzichristodoulou G, Modgil V, Russo GI , Tharakan T et al (2021) What is the effectiveness of surgical and non-surgical therapies in the treatment of ischemic priapism in patients with sickle cell disease? A systematic review. EUROPEAN UROLOGY, Vol. 79 (pp S463-S464)
Malipatil NS, Yadegarfar G, Lunt M, Keevil B, Siddals K, Livingston M, Roberts S, Narayanan P, Rutter M, Gibson JM , Donn R et al (2019) Male hypogonadism: 14‐year prospective outcome in 550 men with type 2 diabetes. Endocrinology, Diabetes & Metabolism, Vol. 2(3)
Kelly DM, Harrison PS, Akhtar S & Jones TH (2014) Testosterone Increases Glucose Uptake and Glycolysis in HepG2 Human Liver Cells. ENDOCRINE REVIEWS, Vol. 35(3)
Bokhamada HK, Woodroofe MN, Jones TH, Small SH, Kay W & Dalton CF (2013) Investigation of the effect of testosterone treatment on the expression of chemokine receptors in monocyte/macrophage THP-1 cell line. Atherosclerosis, Vol. 231(2) (pp e6-e6)
Rao P, Brooke JC, Mclaren D, Walter DJ, Muraleedharan V & Jones TH (2013) Testosterone therapy improves HbA1c and other cardiovascular risk factors in hypogonadal men with poorly controlled diabetes: a retrospective analysis of five years of clinical practice. DIABETIC MEDICINE, Vol. 30 (pp 146-146)
Kelly DM, Sellers DJ, Woodroofe MN, Jones TH & Channer KS (2013) Effect of Testosterone on Inflammatory Markers in the Development of Early Atherogenesis in the Testicular-Feminized Mouse Model. Endocrine Research, Vol. 38(3) (pp 125-138)
Beaudet A, Gilmour L, Church N, Lloyd A, McLeod E & Jones TH (2010) Clinical and cost effectiveness of testosterone replacement in patients with type 2 diabetes mellitus and hypogonadism. Journal of Men's Health, Vol. 7(3) (pp 289-289)
Muraleedharan V, Jones TH & Hassan HMJ (2010) Acute Visual Loss Due to PDE5 Inhibitor Induced Non Arteritic Anterior Ischaemic Optic Neuropathy in a Young Man with Hypogonadism and Erectile Dysfunction.. ENDOCRINE REVIEWS, Vol. 31(3)
Muraleedharan V, Ranjan N, Rolfe C & Jones TH (2010) The Effect of Testosterone Undecanoate on Cardiovascular Risk Factors in Men with Hypogonadism in Clinical Practice.. ENDOCRINE REVIEWS, Vol. 31(3)
Muraleedharan V, Marsh H & Jones TH (2010) Low Testosterone Level Is Associated with Significant Increase in All Cause and Cardiovascular Mortality in Men with Type 2 Diabetes.. ENDOCRINE REVIEWS, Vol. 31(3) (pp S863-S863)
Jones TH (2010) Hypogonadism and Type 2 Diabetes - An evidence based approach. INTERNATIONAL JOURNAL OF ANDROLOGY, Vol. 33 (pp 97-98)
Rigby E, Jones TH & Muraleedharan V (2010) Should Men with Isolated Secondary Hypogonadism with Low or Low Normal Gonadotrophins Have MRI Pituitary Scans? An Audit of 100 Patients.. ENDOCRINE REVIEWS, Vol. 31(3)
Jones TH (2009) HYPOGONADISM IN DIABETES. JOURNAL OF ANDROLOGY, Vol. 30 (pp 13-13)
Malkin CJ, Morris P, Jones TH & Channer KS (2009) Low serum testosterone and increased mortality in men with coronary disease. EUROPEAN HEART JOURNAL, Vol. 30 (pp 774-774)
Salim M, Aung M, Jones TH & Merza Z (2008) Blood pressure control in Type 2 diabetes patients (clinic and 24-hour ambulatory blood pressure monitor comparison). DIABETIC MEDICINE, Vol. 25
Stanworth RD, Kapoor D, Channer KS & Jones TH (2007) Statin use is associated with lower total testosterone levels but not bioavailable or free testosterone in men with Type 2 diabetes. DIABETIC MEDICINE, Vol. 24 (pp 69-69)
Stanworth RD, Kapoor D, Channer KS & Jones TH (2007) HDL cholesterol levels are positively associated with testosterone levels in men with Type 2 diabetes. DIABETIC MEDICINE, Vol. 24 (pp 79-79)
Smith AM, Sandher RK, Bennett RT, Jones TH, Jones RD, Cowen ME & Channer KS (2007) Characterisation of the vasodilatory action of 17 beta oestradiol in the human pulmonary circulation. EUROPEAN HEART JOURNAL, Vol. 28 (pp 57-57)
Hall J, Jones RD, Clarke S, Hopkinson DN, Cooper GJ, Locke TJ, Survana SK, Jones TH & Charmer KS (2006) The vasodilatory action of testosterone is independent of the endothelium, classic androgen receptor, aromatase activity, nitric oxide and dilator prostaglandins in isolated human pulmonary vessels. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 47(4) (pp 344A-345A)
Malkin CJ, Pugh PJ, West JN, Van Beek E, Jones TH & Channer KS (2006) Testosterone therapy in men with moderate severity heart failure: a double blind RCT. EUROPEAN HEART JOURNAL, Vol. 27 (pp 23-23)
Smith AM, Bennett RT, Jones TH, Cowen ME, Channer KS & Jones RD (2006) Characterisation of the vasodilatory action of testosterone in the human pulmonary circulation. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 47(4) (pp 306A-307A)
Malkin CJ, Pugh PJ, West JN, van Beek E, Jones TH & Channer KS (2005) Testosterone therapy in men with heart failure: A double blind placebo controlled trial. HEART, Vol. 91 (pp A20-A21)
Smith AM, Bennett RT, Jones TH, Cowen ME, Channer KS & Jones RD (2005) Characterisation of the vasodilatory action of testosterone in the human pulmonary circulation. THORAX, Vol. 60 (pp II7-II7)
Hall J, Jones RD, Kong P, Jones TH, Peers C & Channer KS (2005) Testosterone inhibits extracellular calcium entry via voltage-gated calcium channels in A7r5 vascular smooth muscle cells at physiological concentrations. HEART, Vol. 91 (pp A43-A43)
Smith AM, Jones RD, Jones TH & Channer KS (2005) A comparison of the vasodilatory action of testosterone in isolated male and female human pulmonary arteries. EUROPEAN HEART JOURNAL, Vol. 26 (pp 610-610)
Scragg JL, Jones RD, Jones TH, Channer KS & Peers C (2004) 1106-186 Testosterone inhibits the α1C subunit of L-tyoe Ca 2+ channels (Ca v 1.2) and α1H T-tyoe Ca 2+ channels (Ca v 3.2) stably expressed in human embryonic kidney 293 cells. Journal of the American College of Cardiology, Vol. 43(5) (pp A494-A494)
Scragg JL, Jones RD, Jones TH, Channer KS & Peers C (2004) Testosterone inhibits calcium currents in A7R5 vascular smooth muscle cells, and in HEK293 cells stably expressing the α1C subunit of L type calcium channels and α1H T type calcium channels. HEART, Vol. 90 (pp A44-A44)
NETTLESHIP J (2003) P2271 The relationship between serum levels of testosterone and inflammatory cytokines in men with coronary artery disease. European Heart Journal, Vol. 24(5) (pp 435-435)
Pugh PJ, Malkin CJ, Morris PD, Nettleship J, Jones RD, Jones TH & Channer KS (2003) Relation of testosterone with inflammatory cytokines in men with coronary artery disease. Journal of the American College of Cardiology, Vol. 41(6) (pp 344-344)
MALKIN C (2003) 3638 Testosterone is a vasodilator of resistance arteries in men with heart failure. European Heart Journal, Vol. 24(5) (pp 709-709)
MALKIN C (2003) 187 Testosterone replacement therapy improves ischaemic threshold and mood in hypogonadal men with angina. European Heart Journal, Vol. 24(5) (pp 20-20)
JONES R (2003) P1780 Testosterone dilates isolated human pulmonary and mesenteric arteries and veins. European Heart Journal, Vol. 24(5) (pp 342-342)
Pugh PJ, Malkin CJ, Morris PD, Asif S, Jones RD, Jones TH & Channer KS (2003) Prevalence of hypogonadism in men with coronary artery disease. Journal of the American College of Cardiology, Vol. 41(6) (pp 344-344)
Rowell KO, Jones RD, Pugh PJ, Jones TH & Channer KS (2003) Comparison of the vasodilatory action of testosterone in isolated human pulmonary and mesenteric arteries and veins. BRITISH JOURNAL OF PHARMACOLOGY, Vol. 138 (pp U76-U76)
Rowell KO, Jones RD, Pugh PJ, Jones TH & Channer KS (2003) Testosterone is an efficacious vasodilator in isolated human pulmonary and mesenteric arteries and veins. HEART, Vol. 89 (pp A30-A30)
Jones RD, Roberts SA, Ruban LN, Pugh PJ, English KM, Jones TH & Channer KS (2003) Testosterone does not increase the intracellular concentration of cGMP in A7r5 aortic smooth muscle cells. BRITISH JOURNAL OF PHARMACOLOGY, Vol. 138 (pp U75-U75)
Roberts SA, Gallagher O, Jones RD, English KM, Jones TH & Channer KS (2002) Quantification of lumen occlusion due to neointimal cell growth in cultured thoracic aortae from testicular feminized and control mice. BRITISH JOURNAL OF PHARMACOLOGY, Vol. 137
Pugh PJ, Jones RD, Nettleship J, Jones TH & Channer KS (2002) Testosterone suppresses cytokine production in whole blood from men with heart failure. BRITISH JOURNAL OF PHARMACOLOGY, Vol. 135
Nettleship JE, Jones RD, Pugh PJ, Jones TH & Channer KS (2002) Serum cytokine levels in male patients with stable coronary artery disease. BRITISH JOURNAL OF PHARMACOLOGY, Vol. 137
Pugh PJ, West JN, Jones TH & Channer KS (2002) Testosterone therapy improves exercise duration and symptoms in men with chronic congestive heart failure. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 39(5) (pp 155A-155A)
Rowell KO, Gill S, Wagstaff J, Jones RD, Pugh PJ, Jones TH & Channer KS (2002) Assessment of the vasodilatory action of testosterone in isolated human pulmonary arteries and veins. BRITISH JOURNAL OF PHARMACOLOGY, Vol. 137
Pugh PJ, Jones TH & Channer KS (2002) Acute haemodynamic effects of testosterone administration in men with heart failure. EUROPEAN HEART JOURNAL, Vol. 23 (pp 28-28)
Jones RD, Ruban LN, Pugh PJ, English KM, Jones TH & Channer KS (2002) Testosterone inhibits agonist-induced increases in intracellular calcium in rat aortic smooth muscle cells. BRITISH JOURNAL OF PHARMACOLOGY, Vol. 135
Jones RD, Pugh PJ, English KM, Jones TH & Channer KS (2002) Isolated arteries from testicular feminised mice have maintained dilator responses to testosterone but reduced vascular reactivity to acetylcholine. BRITISH JOURNAL OF PHARMACOLOGY, Vol. 135
Pugh PJ, Jones RD, Nettleship J, Kerry K, Jones TH & Channer KS (2001) Testosterone suppresses tumour necrosis factor production in whole blood from men with heart failure. EUROPEAN HEART JOURNAL, Vol. 22 (pp 498-498)
English K, Steeds RP, Birchall AS, Jones TH & Channer KS (2000) Low dose transdermal testosterone therapy improves myocardial ischaemia and quality of life in men with chronic stable angina. EUROPEAN HEART JOURNAL, Vol. 21 (pp 364-364)
JONES TH, JUSTICE SK, KENNEDY RL & PRICE A (1992) KININS STIMULATE PHOSPHOINOSITIDE TURNOVER AND HORMONE-RELEASE FROM HUMAN PITUITARY-ADENOMAS - AN ASSOCIATION WITH IL-6 SECRETION. JOURNAL OF ENDOCRINOLOGY, Vol. 135 (pp P91-P91)
BHOOLA KD, CULLEN DR, FIGUEROA CD, JONES TH & SMITH CM (1990) COPRESENCE OF IMMUNOREACTIVE TISSUE KALLIKREIN AND PROLACTIN IN HUMAN ANTERIOR-PITUITARY ADENOMAS. JOURNAL OF PHYSIOLOGY-LONDON, Vol. 422 (pp P57-P57)
JONES TH, BROWN BL & DOBSON PRM (1987) BRADYKININ STIMULATES INOSITOL PHOSPHATE PRODUCTION AND PROLACTIN-RELEASE IN RAT ANTERIOR-PITUITARY-CELLS. JOURNAL OF ENDOCRINOLOGY, Vol. 112 (pp 155-155)
KANDLER RH, JONES TH, BEVAN BR, BROWN BL & CULLEN DR (1987) THE CONTROL OF PROLACTIN SECRETION BY GABA IN PATIENTS WITH PITUITARY-ADENOMAS. JOURNAL OF ENDOCRINOLOGY, Vol. 112 (pp 87-87)
JONES TH, BROWN BL & DOBSON PRM (1986) EVIDENCE THAT ANGIOTENSIN-II IS A PARACRINE AGENT MEDIATING GNRH STIMULATED PROLACTIN SECRETION. JOURNAL OF ENDOCRINOLOGY, Vol. 111 (pp 134-134)
Smith A () Characterization of the vasodilatory action of testosterone in the human pulmonary circulation. Vascular Health and Risk Management, Vol. Volume 4 (pp 1459-1466)

Professional activities and memberships

International and National Committee Membership

President of the Androgen Society (International) 2021-2023

Vice President of Androgen Society 2019-2021

Treasurer of Androgen Society 2017-2019

Chair Academic Sub-committee Association of British Clinical Diabetologists and Committee Member 2014-2020

International and National Guideline and Society Committees

Guideline committee Member for European Association of Urology for Male Hypogonadism (2015-2019) followed by Sexual and Reproductive Health (2020-2024).

Guideline Committee Member British Society for Sexual Medicine Testosterone Therapy 2017 and 2023

International Consultation for Sexual Medicine 2019, 2024 (International Society for Sexual Medicine Committee Member 2022-2023.

Standardisation of Thresholds and Reporting of Testosterone of Male Hypogonadism in UK (Society for Endocrinology, UKNEQAS, Association of Clinical Biochemistry and Laboratory Medicine (ACB) and the International Federation of Clinical Biochemistry (IFCC).

Association of British Clinical Diabetologists (ABCD) Lead for Worldwide Audit of Testosterone in Diabetes 2020 - Present

Parliamentary Working Party for Men’s Health

NHS Diabetes Factsheets Committee (two) on (1) Erectile Dysfunction (2) Diabetes and Hypogonadism 2011

Chair Specialist Executive Committee for the Three Deaneries - Leicester, Nottingham, South Yorkshire for Diabetes and Endocrinology (2007-2010)

Training Programme Director for SpR’s in Diabetes and Endocrinology in South Yorkshire (1999-2010)

Society for Endocrinology Hypogonadism and Aging Statement 2012

Society for Endocrinology, Corporate Liaison Committee Member 2007-2010

Society for Endocrinology Convener for Special Interest Group in Andrology 2010-2013

Editorial Boards

Associate Editor - Therapeutic Advances in Endocrinology and Metabolism (2009-2015)

Androgens: Clinical Research and Therapeutics (2019-2022)

Sub-section Editor Journal of Men Health 2013 to present

Editorial Board: - Clinical Endocrinology (2009-2012)

Nature Scientific Reports (2014-2017)

American Journal of Men’s Health (2011-2023)

British Journal of Diabetes (2014-present)

Androgens Clinical Research and Therapeutics (2019-present)

Media

Testosterone 'could prevent heart and diabetes deaths' - www.bbc.co.uk/news/health-31869054

How many middle-aged men need HRT? - www.bbc.co.uk/news/magazine-27123812

Hormone could treat heart failure - www.bbc.co.uk/1/hi/health/3148771.stm

EASD TV October 2023 through ABCD website

ABCD audits prominent at recent EASD - https://abcd.care/announcement/abcd-audits-prominent-recent-easd

Endocrine Today News Interviews

Link between testosterone and diabetes: Many questions remain - https://www.healio.com/news/endocrinology/20120325/link-between-testosterone-and-diabetes-many-questions-remain

Testosterone replacement may improve death rate in testosterone-deficient men with diabetes - https://www.healio.com/news/endocrinology/20120325/testosterone-replacement-may-improve-death-rate-in-testosterone-deficient-men-with-diabetes

Testosterone therapy reduces CV events, death in men with hypogonadism - https://www.healio.com/news/endocrinology/20190322/testosterone-therapy-reduces-cv-events-death-in-men-with-hypogonadism

TRAVERSE: Men using testosterone replacement do not have increased risk for CV events - https://www.healio.com/news/endocrinology/20230616/traverse-men-using-testosterone-replacement-do-not-have-increased-risk-for-cv-events

Testosterone therapy improves quality of life in men with hypogonadism, type 2 diabetes - https://www.healio.com/news/endocrinology/20220614/testosterone-therapy-improves-quality-of-life-in-men-with-hypogonadism-type-2-diabetes

Testosterone therapy may benefit men with diabetes and obesity, but remains controversial - https://www.healio.com/news/endocrinology/20230412/testosterone-therapy-may-benefit-men-with-diabetes-and-obesity-but-remains-controversial

Testosterone therapy may lower HbA1c for men with type 2 diabetes, hypogonadism - https://www.healio.com/news/endocrinology/20231004/testosterone-therapy-may-lower-hba1c-for-men-with-type-2-diabetes-hypogonadism

Testosterone therapy does not slow progression to diabetes, increase odds for remission - https://www.healio.com/news/endocrinology/20240301/testosterone-therapy-does-not-slow-progression-to-diabetes-increase-odds-for-remission